Technologies transfer
Technology Transfer and Scale-Up
When designing a production line upstream / downstream or small molecule, the understanding of the process is in the heart of matters. Taking the process details and transforming them to a working line on a new site or furthermore in most cases including a scale up of the process from lab or pilot scale to high volume commercial production requires unique engineering capabilities.
Such as in the case of an R&D process for the production of Insulin in the lab with a 60 Liter fermenter to a 2 x 5000 Liter fermenter in a commercial plant thousands of miles away and overseas.
Biopharmax, centered in the heart of an innovative hub for biotech new technologies and products, time after time had gained unique experience in scaling up such technologies from the laboratory R&D scale to a commercial plant scale.
Finding ourselves in between innovative companies with a very attractive variety of technologies and a large international interest for new and advanced technologies, we target to bring value to both technology provider and large scale international manufacturer and seller.
Contact us with your interest whether to allocate new technology or implement it at your new manufacturing facility.
Product and Material
Over 40 years Biopharmax had constructed pharmaceutical and Bio-technology manufacturing plants in North and Central America, Central and Western Europe, Middle East and Asia. Amon these plants are Small molecule Active Pharmaceutical Ingredients (API) as antibiotics, and many large molecules as Monoclonal Antibodies (mAbs), Insulin, Human Growth Hormone (HGH) and some types of vaccines.
At the other end of the supply chain is the formulation and sterile filling, once again an integral part of Biopharmax expertize, with experience of several formulation and aseptic filling lines.
Networked worldwide we have access to several materials and products from which continuously are demanded worldwide and we welcome you to contact us in such inquiry and requirement.
